BNP Paribas Financial Markets Purchases 217,450 Shares of OPKO Health, Inc. (NASDAQ:OPK)

BNP Paribas Financial Markets raised its position in OPKO Health, Inc. (NASDAQ:OPK) by 736.7% during the third quarter, Holdings Channel reports. The fund owned 246,967 shares of the biotechnology company’s stock after acquiring an additional 217,450 shares during the period. BNP Paribas Financial Markets’ holdings in OPKO Health were worth $368,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. FMR LLC increased its position in OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after buying an additional 11,089 shares in the last quarter. Integrated Investment Consultants LLC purchased a new stake in OPKO Health in the third quarter worth about $233,000. Intech Investment Management LLC purchased a new stake in OPKO Health in the third quarter worth about $190,000. Ground Swell Capital LLC purchased a new stake in OPKO Health in the third quarter worth about $63,000. Finally, Highline Wealth Partners LLC purchased a new stake in OPKO Health in the third quarter worth about $174,000. Institutional investors own 64.63% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have commented on OPK. Barrington Research restated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a research report on Friday, November 8th. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research report on Thursday, September 26th. Finally, Piper Sandler restated an “overweight” rating and issued a $3.00 price target on shares of OPKO Health in a research report on Tuesday, September 17th.

OPKO Health Stock Performance

NASDAQ:OPK opened at $1.59 on Friday. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a 12-month low of $0.85 and a 12-month high of $1.76. The stock has a 50-day moving average price of $1.53 and a 200 day moving average price of $1.47. The stock has a market capitalization of $1.09 billion, a P/E ratio of -8.37 and a beta of 1.62.

Insider Buying and Selling

In other news, CEO Phillip Md Et Al Frost purchased 125,000 shares of the business’s stock in a transaction on Friday, December 13th. The stock was acquired at an average price of $1.59 per share, for a total transaction of $198,750.00. Following the acquisition, the chief executive officer now directly owns 212,536,477 shares of the company’s stock, valued at $337,932,998.43. This represents a 0.06 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Over the last 90 days, insiders acquired 1,304,255 shares of company stock worth $2,024,605. 47.26% of the stock is owned by corporate insiders.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.